Cannabinoids In Neurodegenerative Disorders And Stroke/Brain Trauma: From Preclinical Models To Clinical Applications

Neurodegeneration (in general) Stroke Alzheimer's Disease Parkinson's Disease Huntington's Disease Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Neonatal Hypoxia

Key Findings

In this review, we will collect all experimental evidence, mainly obtained at the preclinical level, supporting that different cannabinoid compounds may be neuroprotective in adult and neonatal ischemia, brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's chorea, and amyotrophic lateral sclerosis.

Information and Links


Link: Cannabinoids In Neurodegenerative Disorders And Stroke/Brain Trauma: From Preclinical Models To Clinical Applications

Year: 2015

DOI: 10.1007/s13311-015-0381-7


Ratings

(How Ratings Work)

Neurodegeneration (in general) — 3


Likely probability of the efficacy of cannabis for treatment of Neurodegeneration (in general) according to the results found in this study.

Stroke — 3


Likely probability of the efficacy of cannabis for treatment of Stroke according to the results found in this study.

Alzheimer's Disease — 3


Likely probability of the efficacy of cannabis for treatment of Alzheimer's Disease according to the results found in this study.

Parkinson's Disease — 3


Likely probability of the efficacy of cannabis for treatment of Parkinson's Disease according to the results found in this study.

Huntington's Disease — 3


Likely probability of the efficacy of cannabis for treatment of Huntington's Disease according to the results found in this study.

Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) — 3


Likely probability of the efficacy of cannabis for treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) according to the results found in this study.

Neonatal Hypoxia — 3


Likely probability of the efficacy of cannabis for treatment of Neonatal Hypoxia according to the results found in this study.

Drugs Used

Cannabinoids